FGFR2 and gastric cancer: As monotherapy, the pan-FGFR tyrosine kinase inhibitor (TKI) AZD4547 did not show any improvement in progression-free survival (PFS) in the second-line setting of FGFR2-amplified gastric cancers compared to standard-of-care paclitaxel chemotherapy [85].